Double drug attack: new hope for tough Crohn's cases?

NCT ID NCT06520397

Recruiting now Disease control Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether combining two drugs—upadacitinib and ustekinumab—works better than just increasing the dose of ustekinumab alone for people with Crohn's disease who didn't get enough help from standard treatment. About 214 adults with active Crohn's will be randomly assigned to one of the two treatment groups. The main goal is to see if the combo leads to more people achieving remission (healing of the gut lining) by week 16, while also checking for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: upadacitinib and ustekinumab
What this could lead to: If successful, this could offer a more effective treatment option for people with Crohn's disease who don't respond well to standard doses of ustekinumab alone.
What could go wrong: This is a Phase 4 trial, but it's still relatively small (214 participants) and early results may not apply to all patients. Combining two powerful drugs also raises the risk of side effects like infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CROHN DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Crohn disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CROHN DISEASE

Contacts and locations

Locations

Wei Wang
RECRUITING

Guangzhou, Guangdong, 510000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.